JP2023520927A5 - - Google Patents
Info
- Publication number
- JP2023520927A5 JP2023520927A5 JP2022561477A JP2022561477A JP2023520927A5 JP 2023520927 A5 JP2023520927 A5 JP 2023520927A5 JP 2022561477 A JP2022561477 A JP 2022561477A JP 2022561477 A JP2022561477 A JP 2022561477A JP 2023520927 A5 JP2023520927 A5 JP 2023520927A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- dnaj
- fusion protein
- polyglutamine
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008251P | 2020-04-10 | 2020-04-10 | |
| US63/008,251 | 2020-04-10 | ||
| PCT/US2021/026633 WO2021207636A2 (en) | 2020-04-10 | 2021-04-09 | Compositions and methods for the treatment of protein aggregation disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520927A JP2023520927A (ja) | 2023-05-22 |
| JP2023520927A5 true JP2023520927A5 (enExample) | 2024-03-27 |
Family
ID=75747121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561477A Pending JP2023520927A (ja) | 2020-04-10 | 2021-04-09 | タンパク質凝集障害の処置のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230226223A1 (enExample) |
| EP (1) | EP4132955A2 (enExample) |
| JP (1) | JP2023520927A (enExample) |
| KR (1) | KR20220167324A (enExample) |
| CN (1) | CN115667289A (enExample) |
| AU (1) | AU2021254272A1 (enExample) |
| BR (1) | BR112022020444A2 (enExample) |
| MX (1) | MX2022012525A (enExample) |
| TW (1) | TW202204383A (enExample) |
| WO (1) | WO2021207636A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057858B (zh) * | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| JP2023548632A (ja) * | 2020-10-26 | 2023-11-17 | ソラ・バイオサイエンシズ・エルエルシー | アルツハイマー病の処置のための組成物および方法 |
| EP4686478A1 (en) * | 2024-07-31 | 2026-02-04 | Consejo Superior de Investigaciones Científicas (CSIC) | Qbp1 for use in the treatment and/or prevention of type 2 diabetes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999061601A2 (en) | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
| ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| JP5136766B2 (ja) | 2004-12-15 | 2013-02-06 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラベクター |
| JP2008125455A (ja) * | 2006-11-22 | 2008-06-05 | Sapporo Medical Univ | ポリグルタミン凝集体形成阻害活性を有するポリペプチド |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| EP2524037B1 (en) | 2010-01-12 | 2018-05-16 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| US9169492B2 (en) | 2010-02-05 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
-
2021
- 2021-04-09 KR KR1020227039402A patent/KR20220167324A/ko active Pending
- 2021-04-09 CN CN202180041478.7A patent/CN115667289A/zh active Pending
- 2021-04-09 US US17/995,901 patent/US20230226223A1/en active Pending
- 2021-04-09 JP JP2022561477A patent/JP2023520927A/ja active Pending
- 2021-04-09 EP EP21722705.7A patent/EP4132955A2/en active Pending
- 2021-04-09 TW TW110112984A patent/TW202204383A/zh unknown
- 2021-04-09 BR BR112022020444A patent/BR112022020444A2/pt unknown
- 2021-04-09 MX MX2022012525A patent/MX2022012525A/es unknown
- 2021-04-09 WO PCT/US2021/026633 patent/WO2021207636A2/en not_active Ceased
- 2021-04-09 AU AU2021254272A patent/AU2021254272A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| JP2023524414A5 (enExample) | ||
| JP7801093B2 (ja) | 細胞トランスフェクション及び／又はｒＡＡＶベクター産生の改善のための増強剤 | |
| JP2020522269A5 (enExample) | ||
| JP6619454B2 (ja) | キャプシド | |
| Mori et al. | Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein | |
| ES2230569T3 (es) | Funciones accesorias para uso en la produccion de viriones aav recombinantes. | |
| JP2021512649A5 (enExample) | ||
| Lu | Recombinant adeno-associated virus as delivery vector for gene therapy—a review | |
| JP2022508182A5 (enExample) | ||
| JP2023520927A5 (enExample) | ||
| RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| TW201629225A (zh) | 第九因子基因療法 | |
| JP2023529371A5 (enExample) | ||
| JP2023537358A5 (enExample) | ||
| US11780886B2 (en) | Modified viral vectors and methods of making and using the same | |
| JP2023541444A5 (enExample) | ||
| JP2022542829A5 (enExample) | ||
| JP2018536432A5 (enExample) | ||
| Mochizuki et al. | using various kinds of promoters and serotypes | |
| US10105450B2 (en) | Promoter compositions | |
| JP2020533313A5 (enExample) | ||
| RU2021117249A (ru) | Модулирующие полинуклеотиды | |
| JP2023548632A5 (enExample) | ||
| Stiefelhagen et al. | 865. Focus on Specificity: Creating Efficient CML-Specific Recombinant Adeno-Associated Viral (AAV) Vectors Using a Random Peptide Library |